Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions

被引：1
|
作者：
Goldberg, R. [1 ]
Beswick, L. [2 ]
Van Langenberg, D. [3 ]
Sally, B. [4 ,5 ]
Rosella, O. [2 ]
Gibson, P. [2 ]
Moore, G. [1 ]
机构：
[1] Monash Univ, Monash Hlth, Dept Gastroenterol, Melbourne, Vic 3004, Australia
[2] Alfred Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60498-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P378
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 50 条
  • [1] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [2] Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays
    Vroemen, Wim H. M.
    Agata, Shakira S.
    van Beers, Joyce J. B. C.
    Damoiseaux, Jan G. M. C.
    [J]. ANTIBODIES, 2024, 13 (03)
  • [3] MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES
    Westerlund, Johanna
    Jokiranta, T. Sakari
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (04) : 325 - 325
  • [4] USEFULNESS OF MONITORING THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASES THROUGH THE DETERMINATION OF INFLIXIMAB OR ADALIMUMAB TROUGH LEVELS AND BY THE EVALUATION OF ANTI-DRUG ANTIBODIES
    Miranda, A.
    Sgambato, D.
    Ferrante, E.
    Picascia, D.
    Avallone, L.
    D'Amico, M.
    Sullo, M. G.
    Capuano, A.
    Romano, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E133 - E133
  • [5] Tolerating infliximab therapeutic drug monitoring without anti-drug antibodies - an argument for drug intolerant assays?
    Carlson, S.
    Evgeniou, V.
    Kok, K.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 894 - 895
  • [6] The association between drug levels, anti-drug antibodies, and therapeutic response during infliximab therapy in pediatric Crohn's disease
    Stein, R. E.
    Lee, D. Y.
    Leonard, M. B.
    Thayu, M.
    Herskovitz, R. M.
    Kerbowski, T.
    Baldassano, R. N.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S434 - S434
  • [7] Infliximab and Adalimumab Therapeutic Drug Monitoring (TDM): Analysis of >125,000 Patient Samples for Drug Levels and Designation of Anti-Drug Antibodies into Low, Intermediate and High Titers
    Chun, Kelly Y.
    Bastidas, Monique
    Lehrhoff, Andrew
    Zikry, Michael
    Yang, Jane M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S37 - S37
  • [8] Therapeutic Drug Monitoring of the Biosimilar (AMJEVITA™, Adalimumab-atto) Using Labcorp Adalimumab Assay for Drug Level and Anti-Drug Antibodies
    Chun, Kelly Y.
    Bastidas, Monique
    Yeo, Lythou
    Magpantay, Susie
    Scott, Judah
    Zikry, Michael
    Galdamez, Wayne
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S5 - S6
  • [9] Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring
    Barlow, Nicola L.
    Mohammed, Pervaz
    Berg, Jonathan D.
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2016, 53 (04) : 477 - 484
  • [10] Factors that may influence the development of anti-drug antibodies to adalimumab
    Reinisch, W.
    Rauter, I.
    Chen, L.
    Gessner, M.
    Fanjiang, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S429 - S430
12345